Document Detail

Daily and intermittent Rosuvastatin 5mg therapy in statin intolerant patients: an observational study.
MedLine Citation:
PMID:  22256801     Owner:  NLM     Status:  Publisher    
Abstract Objective: To examine the efficacy and tolerability of rosuvastatin 5 mg at daily and non-daily dosing regimens. Research Design & Methods: A retrospective survey was conducted at 9 primary, secondary and tertiary healthcare centres in the United Kingdom. Main Outcome Measures: Changes in lipid fractions from baseline values after more than 3 months treatment. Results: 325 patients were identified. These patients were aged 63±10 years, 50% male and prescription was mostly for primary prevention of cardiovascular disease (CVD) (59%). Co-morbidities included: established CVD present in 42%, type 2 diabetes mellitus (15%), hypertension (74%) and smoking (9%). Adverse effects had been documented to simvastatin (75%) or atorvastatin (63%). 289 patients (89%) tolerated rosuvastatin well and were still adherent after a median follow-up of 14.9 (3-79) months. The remainder (n=36; 11%) discontinued the medication after median 5 months' treatment due to adverse effects. Efficacy was assessed in 215 patients who had adequate data. Baseline lipids were total cholesterol (TC) 7.41±1.50mmol/L, triglycerides (TG) 2.26 (range 0.36-18.4) mmol/L; high density lipoprotein cholesterol (HDL-C) 1.43±0.47mmol/L and low density lipoprotein cholesterol (LDL-C) 4.76±1.38mmol/L. Daily rosuvastatin (n=134) reduced mean TC by 31%, TG 15% and LDL-C 43% (p<0.001). Rosuvastatin 5 mg 2-3 times weekly (n=79) reduced TC 26%, TG 16% and LDL-C 32% (p<0.001). Weekly rosuvastatin (n=11) reduced TC 17%, LDL-C by 23% (p<0.001) but had no effect on TGs. Targets were attained in 17% of CHD-risk equivalent patients and 41% of primary prevention patients by National Cholesterol Education Program criteria and 27% and 68% using UK targets. No myositis or rhabdomyolysis was observed and alanine aminotransferase (ALT) and creatine kinase (CK) were similar to baseline. Conclusions: In this retrospective observational multicentre study, rosuvastatin 5mg was found to be safe and biochemically effective either as daily or intermittent therapy in patients intolerant to other conventional statin regimens.
Claire Meek; Anthony S Wierzbicki; Christina Jewkes; Patrick J Twomey; Martin A Crook; Alan Jones; Adie Viljoen
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-18
Journal Detail:
Title:  Current medical research and opinion     Volume:  -     ISSN:  1473-4877     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development of a Family Functioning Scale for Major Depressive Disorder.
Next Document:  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.